Hyperliquid Posts $1.2M Loss Pre-Merger, Secures $1B Equity Line

TL;DR

**PURR is a pre-revenue SPAC-like entity with a massive post-merger capital raise, but its future hinges on volatile HYPE token prices.**

AI Summary

Hyperliquid Strategies Inc (PURR) reported a net loss of $1,212,921 for the period from its inception on July 2, 2025, through September 30, 2025, with basic and diluted net loss per share at $13,183.92. The company generated no revenues during this period, with all activities related to its formation and preparation for a proposed business combination. Total current liabilities amounted to $1,212,921, primarily consisting of accounts payable and accrued expenses of $1,138,335 and $74,586 due to related parties. Post-quarter, on December 2, 2025, PURR completed a business combination with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC, which significantly alleviated prior substantial doubt about its going concern status by raising capital through subscription agreements. The company also entered into a purchase agreement with Chardan Capital Markets LLC on October 22, 2025, allowing it to sell up to $1,000,000,000 of common stock. However, its financial condition remains substantially dependent on the market price and liquidity of HYPE tokens, which are subject to extreme volatility.

Why It Matters

This filing reveals Hyperliquid Strategies Inc.'s foundational financial state before its significant business combination with Sonnet BioTherapeutics and Rorschach I LLC. For investors, the initial $1.2 million net loss and zero revenue highlight the pre-operational phase, while the subsequent $1 billion equity line with Chardan Capital Markets LLC signals a strong capital injection and future growth potential. Employees and customers of the combined entity will see a more stable financial footing, but the heavy reliance on HYPE token value introduces substantial cryptocurrency market risk, differentiating PURR from traditional biotech or financial firms and placing it in a unique competitive position at the intersection of traditional finance and digital assets.

Risk Assessment

Risk Level: high — The company's financial condition is 'substantially dependent on the market price and liquidity of HYPE tokens,' which are 'subject to extreme volatility and limited trading venues.' This concentration of treasury assets in HYPE tokens, a native cryptocurrency, introduces significant market risk, as 'the Company's financial results and carrying value of its digital assets will fluctuate materially based on HYPE token price movements.'

Analyst Insight

Investors should approach PURR with caution, recognizing its speculative nature. While the $1 billion equity line provides substantial liquidity, the company's direct exposure to HYPE token volatility means it's essentially a bet on the success and adoption of the Hyperliquid protocol. Monitor HYPE token price movements and the company's post-merger operational updates closely before considering an investment.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

$1,212,921

net Income

-$1,212,921

eps

-$13,183.92

gross Margin

N/A

cash Position

$0

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $1.21M — Net Loss (Incurred from inception (July 2, 2025) through September 30, 2025, reflecting pre-operational phase.)
• $13,183.92 — Net Loss Per Share (Basic and diluted net loss per share for the initial operating period.)
• $1.00B — Equity Purchase Agreement (Amount Chardan Capital Markets LLC agreed to purchase in common stock, providing significant post-merger capital.)
• 0 — Revenue (No revenues generated from inception through September 30, 2025, as company was in formation.)
• 127,025,563 — Shares Outstanding (As of December 5, 2025, indicating post-merger share count.)
• $1,212,921 — Total Current Liabilities (As of September 30, 2025, primarily accounts payable and related party debt.)

Key Players & Entities

• Hyperliquid Strategies Inc (company) — Registrant and issuer of PURR common stock
• Sonnet BioTherapeutics Holdings, Inc. (company) — Company acquired in the business combination
• Rorschach I LLC (company) — Company acquired in the business combination and sole investor prior to merger
• Chardan Capital Markets LLC (company) — Purchaser in the $1,000,000,000 common stock purchase agreement
• HYPE tokens (other) — Native cryptocurrency of the Hyperliquid protocol, a key treasury asset
• $1,212,921 (dollar_amount) — Net loss for the period from inception to September 30, 2025
• $13,183.92 (dollar_amount) — Basic and diluted net loss per share for the period
• $1,000,000,000 (dollar_amount) — Maximum amount of common stock Chardan Capital Markets LLC agreed to purchase
• December 2, 2025 (date) — Closing Date of the business combination
• September 30, 2025 (date) — End of the reporting quarter

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company incurred a net loss of $1,212,921 from inception through September 30, 2025, with no revenue. Total current liabilities were $1,212,921. This raised substantial doubt about its ability to continue as a going concern prior to the business combination.
• HYPE Token Volatility [high — market]: The company's financial condition is substantially dependent on the market price and liquidity of HYPE tokens. These tokens are subject to extreme volatility, posing a significant risk to the company's value and operational stability.
• Dependence on Capital Infusion [high — financial]: The company's ability to continue operations is heavily reliant on capital raised through subscription agreements and potential future sales under the purchase agreement with Chardan Capital Markets LLC, which allows for up to $1,000,000,000 in common stock sales.
• Pre-Revenue Stage Operations [medium — operational]: As of September 30, 2025, the company had generated no revenue and all activities were related to its formation and preparation for a business combination. This indicates a lack of established business operations and revenue streams.
• Related Party Liabilities [low — financial]: The company had $74,586 in liabilities due to related parties as of September 30, 2025. While this is a relatively small amount, it indicates potential conflicts of interest or financial arrangements that require careful management.

Industry Context

Hyperliquid Strategies Inc. operates in a rapidly evolving digital asset and biotechnology landscape. The company's strategy appears to involve leveraging digital assets (HYPE tokens) in conjunction with biotechnology operations post-business combination. This dual focus places it at the intersection of highly volatile technology markets and the capital-intensive, R&D-driven biotech sector.

Regulatory Implications

The company's reliance on HYPE tokens subjects it to the evolving regulatory landscape of digital assets, which can vary significantly by jurisdiction and is prone to rapid changes. Compliance with securities laws related to the sale of common stock under the Chardan Capital Markets LLC agreement is also a key regulatory consideration.

What Investors Should Do

1. Monitor HYPE token volatility and its impact on financial condition.
2. Analyze the post-business combination financial statements closely.
3. Evaluate the utilization of the $1,000,000,000 common stock purchase agreement.
4. Assess the integration and operational synergy post-merger.

Key Dates

• 2025-07-02: Company Inception — Marks the beginning of Hyperliquid Strategies Inc.'s corporate existence and the start of its financial reporting period.
• 2025-09-30: End of Reporting Period — The date as of which the condensed consolidated financial statements are presented, showing a net loss and significant liabilities.
• 2025-10-22: Purchase Agreement with Chardan Capital Markets LLC — Established a facility to sell up to $1,000,000,000 of common stock, providing a significant potential source of future capital.
• 2025-12-02: Business Combination Completion — Merger with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC, which significantly improved the company's going concern status by raising capital.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company has incurred more expenses than revenues since its formation, totaling $1,212,921 as of September 30, 2025.)

Going concern

The assumption that a business will continue to operate for the foreseeable future. (Substantial doubt about the company's going concern status was alleviated by post-quarter financing, highlighting its prior precarious financial state.)

Business combination

The acquisition of one company by another, or the merging of two companies into a single new entity. (The company completed a significant business combination with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC, fundamentally changing its structure and financial outlook.)

HYPE tokens

Digital assets whose market price and liquidity are critical to the company's financial condition. (The company's financial health is directly tied to the extreme volatility of these tokens, representing a key market risk.)

Par value

A nominal value assigned to a share of stock by the company's charter, often a very small amount. (The common stock has a par value of $0.01, with only 100 shares issued and outstanding as of September 30, 2025, prior to the business combination.)

Year-Over-Year Comparison

As this is the company's initial 10-Q filing from its inception on July 2, 2025, there is no prior period filing to compare against. The reported period reflects the company's formation costs, resulting in a net loss of $1,212,921 and zero revenue. Key developments like the business combination and the equity purchase agreement occurred post-quarter, significantly altering the company's financial outlook and going concern status.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share PURR The Nasdaq Stock Mar
• $25,000 — tock. The Company was required to pay a $25,000 fee upon execution of the Facility and
• $125,000 — upon execution of the Facility and paid $125,000 on the Closing Date. Additional commitm
• $250,000 — of shares sold by the Company including $250,000 payable once the Company has received a
• $25,000,000 — he Company has received an aggregate of $25,000,000 in proceeds from sales of Common Stock
• $625,000 — Stock under the Purchase Agreement and $625,000 payable once the Company has received a
• $50,000,000 — he Company has received an aggregate of $50,000,000 in proceeds from sales of Common Stock

Filing Documents

• d47504d10q.htm (10-Q) — 258KB
• d47504dex311.htm (EX-31.1) — 10KB
• d47504dex312.htm (EX-31.2) — 10KB
• d47504dex321.htm (EX-32.1) — 3KB
• d47504dex322.htm (EX-32.2) — 3KB
• 0001193125-25-311400.txt ( ) — 1839KB
• purr-20250930.xsd (EX-101.SCH) — 341KB
• d47504d10q_htm.xml (XML) — 135KB

Financial Information

Part I. Financial Information 1

Interim Financial Statements

Item 1. Interim Financial Statements 1 Condensed Consolidated Balance Sheet (Unaudited) 1 Condensed Consolidated Statement of Operations (Unaudited) 2 Condensed Consolidated Statement of Changes in Stockholder's Deficit (Unaudited) 3 Condensed Consolidated Statement of Cash Flows (Unaudited) 4 Notes to Condensed Consolidated Financial Statements (Unaudited) 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 20

Controls and Procedures

Item 4. Controls and Procedures 20

Other Information

Part II. Other Information 21

Legal Proceedings

Item 1. Legal Proceedings 21

Risk Factors

Item 1A. Risk Factors 21

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 21

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 21

Other Information

Item 5. Other Information 21

Exhibits

Item 6. Exhibits 22

Signatures

Part III. Signatures 23 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item1. Interim Financial Statements. HYPERLIQUID STRATEGIES INC. CONDENSED CONSOLIDATED BALANCE SHEET September 30, 2025 Liabilities and Stockholder's Deficit Accounts payable and accrued expenses $ 1,138,335 Due to related parties 74,586 Total Current Liabilities and Total Liabilities 1,212,921 Commitments and Contingencies Stockholder's Deficit: Common stock, $ 0.01 par value; 1,000 shares authorized; 100 shares issued and outstanding — Accumulated deficit ( 1,212,921 ) Total Stockholder's Deficit ( 1,212,921 ) Total Liabilities and Stockholder's Deficit $ — The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of Contents HYPERLIQUID STRATEGIES INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS For the period from July 2, 2025 (inception) through September 30, 2025 Formation and operating costs $ ( 1,212,921 ) Net loss $ ( 1,212,921 ) Basic and diluted weighted average shares outstanding 92 Basic and diluted net loss per share $ ( 13,183.92 ) The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of Contents HYPERLIQUID STRATEGIES INC. CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER'S DEFICIT For the period from July 2, 2025 (inception) through September 30, 2025 Additional Total Paid-In Accumulated Stockholder's Shares Amount Capital Deficit Deficit Balance as of July 2, 2025 (inception) — $ — $ — $ — $ — Issuance of Common Stock 100 — — — — Net loss — — — ( 1,212,921 ) ( 1,212,921 ) Balance as of September 30, 2025 100 $ — $ — $ ( 1,212,921 ) $ ( 1,212,921 ) The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents HYPERLIQUID STRATEGIES INC. CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS For the per

View Full Filing

View this 10-Q filing on SEC EDGAR